Flputnam Investment Management Co. Increases Stake in Stryker Corporation $SYK

Flputnam Investment Management Co. raised its holdings in shares of Stryker Corporation (NYSE:SYK) by 64.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 137,133 shares of the medical technology company’s stock after buying an additional 53,552 shares during the quarter. Flputnam Investment Management Co.’s holdings in Stryker were worth $43,175,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of SYK. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker in the fourth quarter worth about $26,000. Sankala Group LLC acquired a new stake in Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new position in Stryker in the 4th quarter worth approximately $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker during the 4th quarter worth approximately $28,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. 4.60% of the stock is owned by insiders.

Analysts Set New Price Targets

SYK has been the subject of a number of analyst reports. Leerink Partners dropped their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Royal Bank Of Canada reduced their price objective on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. UBS Group started coverage on Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 price objective on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Finally, Robert W. Baird set a $385.00 target price on Stryker in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Down 0.1%

Shares of NYSE SYK opened at $338.80 on Monday. The company has a market capitalization of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a 50 day simple moving average of $324.61 and a 200-day simple moving average of $333.40. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.